

233th Business Plan Presentations Held on December 14, 2021
SHINYOKOHAMA-3CHOME-DAIHOI

1. NISHIKAZE GIKEN K.K. President Mr. Shinichi Nishiura

<https://nishikazegiken.jimdo.com/>(Japanese)

Established in May 2015 Capital stock: USD \$ 10,000

NISHIKAZE GIKEN conceives and develops technology related to renewable energy and semiconductor fabrication equipment.

Due to several issues, there have thus far been few cases of practical utilization as regards the kinds of vibration power generation that are generally known. The company succeeded in the development of technology for power generation combining electromagnetic induction and the inverse magnetostriction effect. It patented a system that is rechargeable, has a high generative capability, and, moreover, can be produced at low cost. Mr. Nishiura described this system and said his company was looking for a partner for joint commercialization of it.

【Re-Cap】 Vibration power generation is the optimal type of power generation for outdoor IoT products, and the key technology is the power source. NISHIKAZE GIKEN's system features increased power and a super capacitor enabling high-capacity recharging. Because it has already acquired the core patent, Mr. Nishiura said it was in the process of planning the vertical launch of a group of products related to the social infrastructure. It is issuing a call for business firms that could assist its development and sale of IoT products with this mechanism built right into them.



2. Kort Valuta Inc. President Mr. Hideki Shibata <https://www.kortvaluta.com/?lang=en>

Established in August 2014 Capital stock: USD \$3,975,000

Kort Valuta is developing issuance and payment applications for prepaid Visa cards targeting closed markets. Its services are not confined to prepayment with employee ID cards; it is extending them to patient registration cards, membership IDs, and student IDs. It is also making preparations for prompt handling of digital wage payment, which is now on the way.

【Re-Cap】 At the start of his presentation, Mr. Shibata informed the audience that “Kort Valuta,” the name of his company, is Swedish for “card value.” The company’s key strength is its use of the world’s fastest processing technology, which enables the instantaneous completion of payment as soon as the holder exits the gate. It is seeking referrals to companies, real properties, hospitals, local governments, and financial institutions that could use its services.



3. ReqMed Company, Ltd. President Mr. Tadashi Matsumoto <http://reqmed.co.jp/eng/>

Established in May 1998 Capital stock: USD \$3,800,000

ReqMed Company is engaged in the development of pharmaceuticals, with a focus on those for unmet needs. Several of its programs are at the late stage of development.

It is taking aim at maximizing its earnings by doing all of the development by itself and using a combination of independent and consigned sales after receiving approval for pharmaceutical manufacture and sale. It aspires to the creation of a larger corporate value than could be obtained through licensing business.



	Disease indication	Development stage
1. Cholic acid	Inborn errors of bile acid metabolism ※1	Preparation for application for approval of manufacture and sale
2. Pentosan	Osteoarthritis of the knee	Start of late Phase II clinical trials
3. Pentosan	Mucopolysaccharidosis, mucolipidosis ※2	Completion of late Phase II clinical trials
4. Pentosan	HTLV-1 associated myelopathy ※2	Completion of early Phase II clinical trials
5. Eltoprazine	L-DOPA-induced dyskinesia ※2	Completion of early Phase II clinical trials

1. Receipt of designation as a pharmaceutical for rare diseases
2. Intention to apply for designation as a pharmaceutical for rare diseases

【Re-Cap】 This time, Mr. Matsumoto made a presentation online, from the United States. ReqMed Company has entered the phase of expansion, and has several programs in the later stage of clinical trials. Mr. Matsumoto emphasized three points, as follows. 1) The company is taking aim at initial public offering (IPO), and needs funds to further develop pharmaceuticals in the late development stage over the next three years. 2) It wishes to effect a steep increase in its staff along with its independent development work. 3) It also intends to reinforce its administrative division in order to bolster its setup for timely disclosure going forward. It is asking for support with each of these agenda.

【Message from Vice Chairman Masatoshi Go】

Covid-19 made this year another hard one, but we managed to hold the Business Plan Presentations meetings throughout it while adjusting to the circumstances.

Although many people have participated online so far, an increasing number have come to the venue since the state of emergency was lifted. I think this may reflect desires to establish people-to-people horizontal relationship that would be difficult to make through online. This Business Plan Presentations meeting was the last one of this year. We are going to hold the meetings in 2022 beginning in February. While it is not clear what the situation will be at that time as far as the pandemic is concerned, we plan to continue introducing small and medium enterprises and venture firms by making arrangements for both online participation and attendance at the venue.

We are counting on your continued assistance and support, and are looking forward to seeing you again in 2022!



《Impressions》

This last Business Plan Presentations meeting of 2021 attracted an audience of about 40 people who participated either online or at the venue. We earnestly hope to hear presentations by many appealing companies again in 2022.

Best wishes for a happy holiday season!